Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug zolucatetide.
Despite all the noise around upcoming massive IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Parabilis sets a record with a $670M biotech IPO
Parabilis Medicines prices upsized IPO at $20 per share, raising $670 million above expected range
Parabilis Medicines 33.5M share IPO priced at $20.00
Small Biotech Catapults To Record High On $10.6 Billion Deal
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Novo underwhelmed by drug it once fought Pfizer for
Gilead and Merck's latest trial success and flop
How Poolbeg Pharma could unlock immunotherapy's biggest problem
